ALB and coronary artery disorder: Targeting this pathway with mTOR inhibitors, such as albumin-bound sirolimus (rapamycin), is being studied in phase I/Ib trials to determine its safety profile and toxicities in patients with PAH, including PAH-CHD (repaired greater than 1 year prior to screening) after being well studied to be safe and beneficial in animal models [98,99,100].